Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Multiple Myeloma
100%
Radiovirotherapy
100%
MV-NIS
85%
Myeloma Cells
57%
Virus
42%
Radioiodine
42%
Myeloma
42%
I-131
42%
Bone Marrow Toxicity
28%
Chloride Channel
28%
Vesicular Stomatitis Virus
28%
Improved Treatment Outcome
28%
Clinical Trials
14%
Radiosensitivity
14%
Recombinant Measles Virus
14%
Syngeneic
14%
Oncolytic Virotherapy
14%
Current Therapies
14%
Oncolytic Potency
14%
Bortezomib
14%
Oncolytic Vesicular Stomatitis Virus
14%
Viable Approach
14%
Plasma Cell Myeloma
14%
Therapeutic Index
14%
Specific Aims
14%
Infected Cells
14%
Efflux
14%
Phase I Trial
14%
Human Sodium Iodide Symporter (hNIS)
14%
NIS Gene
14%
Tumor Cell Death
14%
Lethal Effects
14%
Channel Expression
14%
Mammalian Cells
14%
5TGM1
14%
Xenograft Model
14%
Non-invasive Imaging
14%
Tumor
14%
Surface Membrane
14%
Proteasome Inhibitor Bortezomib
14%
Ionizing Radiation
14%
Radioactive Iodine
14%
Therapeutic Dose
14%
Short Hairpin RNA (shRNA)
14%
Medicine and Dentistry
Multiple Myeloma
100%
Myeloma Cell
80%
Radioactive Iodine
80%
Vesiculovirus
60%
Iodine 131
60%
Virus
60%
Myeloma
60%
Dexamethasone
40%
Bone Marrow Toxicity
40%
Treatment Outcome
40%
Bortezomib
40%
Clinical Trial
40%
Chloride Channel
40%
Radiosensitivity
20%
Effusion
20%
Mammalian Cell
20%
Ionizing Radiation
20%
Cell Killing
20%
Tumor Cell
20%
Sodium Iodide Symporter
20%
Measles Virus
20%
Short Hairpin RNA
20%
Oncolytic Virotherapy
20%
Proteasome Inhibitor
20%
Neoplasm
20%
Xenograft
20%
Therapeutic Window
20%
Diseases
20%
Imaging Technique
20%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Myeloma
100%
Radioactive Iodine
57%
Virus
42%
Vesiculovirus
42%
Iodine-131
42%
Clinical Trial
28%
Chloride Channel
28%
Bortezomib
28%
Bone Marrow Toxicity
28%
Dexamethasone
28%
Neoplasm
28%
Sodium Iodide Symporter
14%
Ionizing Radiation
14%
Effusion
14%
Measles Virus
14%
Proteasome Inhibitor
14%
Short Hairpin RNA
14%
Virotherapy
14%
Diseases
14%
Therapeutic Window
14%